SA
SMMT icon

Sovran Advisors’s Summit Therapeutics SMMT Stock Holding History

Sovran Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-150,047
Closed -$3.45M – 547
2025
Q2 		$3.45M Buy
150,047
+3,519
+2% +$80.2K 0.36% 75
2025
Q1 		$3.61M Buy
146,528
+29,354
+25% +$589K 0.47% 51
2024
Q4 		$1.95M Buy
+117,174
New +$2.27M 0.28% 93

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return

Sovran Advisors's SMMT Position: Q3 2025 in Review

Sovran Advisors sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 150,047 shares — an estimated $3.45M sold.

Sovran Advisors first reported a position in SMMT in Q4 2024 and held it in 3 quarters. The position peaked at $3.61M in Q1 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Sovran Advisors reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sovran Advisors sold 150,047 Summit Therapeutics shares in Q3 2025, an estimated $3.45M.
  • Sovran Advisors first reported a position in Summit Therapeutics in Q4 2024 and held it in 3 quarters.
  • Sovran Advisors's Summit Therapeutics position peaked at $3.61M in Q1 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Sovran Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.